Kobo Biotech Intrinsic Value
Kobo Biotech (KOBO) median intrinsic value is ₹23.04 from 1 valuation models (range ₹23–₹23), vs current price ₹9.63 — +139.3% upside (Trading Below Calculated Value), margin of safety 58.2%. Read KOBO dividend history for the complete payout history and dividend yield track record.
KOBO Valuation Methods Summary — DCF, Graham Number & P/E
Kobo Biotech intrinsic value across 1 models vs current price ₹9.63 — upside/downside and value range per method. For current market price and key ratios, visit KOBO share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹23.04 | ₹20.74 - ₹25.34 | +139.3% | Book Value/Share: ₹23.04, P/B: 1.0x |
KOBO Intrinsic Value vs Market Price — All Valuation Models
Kobo Biotech fair value range ₹23–₹23 vs current market price ₹9.63 across 1 valuation models. Analyse KOBO shareholder distribution to track promoter, FII and institutional holdings.
KOBO Intrinsic Value Analysis — Undervalued or Overvalued?
Kobo Biotech median intrinsic value ₹23.04, current price ₹9.63 — Trading Below Calculated Value by 139.3%, margin of safety 58.2%.
What is the intrinsic value of KOBO?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Kobo Biotech (KOBO) is ₹23.04 (median value). With the current market price of ₹9.63, this represents a +139.3% variance from our estimated fair value.
The valuation range spans from ₹23.04 to ₹23.04, indicating ₹23.04 - ₹23.04.
Is KOBO undervalued or overvalued?
Based on our multi-method analysis, Kobo Biotech (KOBO) appears to be trading below calculated value by approximately 139.3%.
KOBO Financial Health — Key Ratios vs Industry Benchmarks
Kobo Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.67 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 7.47 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
KOBO Cash Flow Quality — Operating & Free Cash Flow
Kobo Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2015 | ₹7 Cr | ₹5 Cr | Positive Free Cash Flow | 8/10 |